What is the most appropriate antihypertensive medication regimen for an African American patient hospitalized with hypertension?

Best Hypertension Medication for African American Hospitalized Patients

For an African American patient hospitalized with hypertension, initiate combination therapy with a calcium channel blocker (CCB) plus either a thiazide-type diuretic or an ARB, rather than monotherapy with an ACE inhibitor or ARB alone.

Initial Treatment Strategy

The most recent and authoritative guidelines—the 2020 International Society of Hypertension (ISH) 1 and 2017 ACC/AHA 2—provide clear, race-specific recommendations for African American patients:

First-Line Therapy for Black Patients

Start with combination therapy immediately 1:

• Low-dose ARB + DHP-CCB (e.g., amlodipine), OR
• DHP-CCB + thiazide/thiazide-like diuretic (chlorthalidone 12.5-25 mg or indapamide 1.5 mg)

This differs from non-Black patients, who typically start with ACE inhibitor or ARB monotherapy 1.

Why Combination Therapy First?

African American patients typically require ≥2 antihypertensive medications to achieve adequate blood pressure control 2. Most Black patients with hypertension, especially in the hospital setting where BP is often severely elevated, will need multiple agents from the outset 2.

Evidence-Based Drug Selection

Preferred Agents (Class I Recommendation)

1. Calcium Channel Blockers (CCBs): More effective at lowering BP in Black patients than RAS inhibitors or beta-blockers 2

   • Amlodipine is as effective as chlorthalidone and superior to lisinopril for reducing BP, CVD, and stroke events in Black patients 2

2. Thiazide-Type Diuretics: Superior to RAS inhibitors for BP reduction and CVD event prevention in Black patients 2

   • Chlorthalidone 12.5-25 mg daily (preferred over hydrochlorothiazide for outcome data) 2
   • Indapamide 1.5 mg modified-release 3

When to Add or Use RAS Inhibitors

ARBs are preferred over ACE inhibitors in Black patients when RAS blockade is indicated 1:

• Black patients have 1.3 times greater risk of angioedema with ACE inhibitors 2
• Use RAS inhibitors as part of combination therapy, not monotherapy 2

Specific indications for RAS inhibitors in Black patients 2:

• Chronic kidney disease with proteinuria or microalbuminuria
• Heart failure with reduced ejection fraction
• Diabetes with nephropathy

Stepwise Treatment Algorithm for Hospitalized Black Patients

Step 1: Initial Combination

• ARB + CCB, OR
• CCB + thiazide diuretic 1

Step 2: Increase to Full Dose

• Titrate both agents to maximum tolerated doses 1

Step 3: Add Third Agent

• Add the missing component: diuretic if not already included, or ARB/ACE inhibitor 1
• Target: CCB + thiazide + ARB/ACE inhibitor triple therapy 1

Step 4: Resistant Hypertension

If BP remains uncontrolled on optimal triple therapy 1, 4:

• Add spironolactone 12.5-50 mg daily (first choice for resistant hypertension) 4
• Alternatives if spironolactone not tolerated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker 1

Critical Pitfalls to Avoid

1. Starting with ACE Inhibitor or ARB Monotherapy

This is less effective in Black patients without comorbidities (CKD, HF, diabetes with nephropathy) 2. Monotherapy with RAS inhibitors shows reduced BP response and potentially worse CVD outcomes compared to CCBs or diuretics 2.

2. Underdosing Thiazide Diuretics

Use chlorthalidone 12.5-25 mg (not lower doses) or hydrochlorothiazide 25-50 mg, as lower doses are unproven or less effective in clinical outcome trials 2.

3. Avoiding RAS Inhibitors Entirely

While not first-line monotherapy, RAS inhibitors are essential components of multidrug regimens and should not be excluded based on race alone 2. The combination of ACE inhibitor/ARB + CCB or thiazide produces similar BP lowering in Black and White patients 2.

4. Delaying Combination Therapy

In the hospital setting with elevated BP, do not start with monotherapy and wait to add a second agent 1. Black patients typically need combination therapy from the start.

Target Blood Pressure

• Target: <130/80 mmHg 1
• Achieve target within 3 months 1
• For elderly or frail patients, individualize based on tolerability 1

Special Considerations for Hospitalized Patients

Comorbidity-Specific Modifications

Heart Failure: Add beta-blocker to the regimen 2

Chronic Kidney Disease: RAS inhibitors (preferably ARB) become essential as part of combination therapy 2

Diabetes with Nephropathy: ARB + CCB or thiazide diuretic 2

Post-MI or Coronary Disease: Add beta-blocker 2

Monitoring and Adjustment

• Review and modify treatment every 2-4 weeks until BP controlled 5
• Check electrolytes and renal function within 1 month when adding diuretics or spironolactone 3
• Monitor for angioedema if ACE inhibitor used (higher risk in Black patients) 2

Contemporary Perspective on Race-Based Prescribing

While current guidelines provide race-specific recommendations, emerging evidence 6, 7 suggests that within-group variation in BP response may exceed between-group differences. However, the most recent high-quality guidelines 1 from 2020 maintain distinct treatment algorithms for Black patients based on consistent evidence of differential monotherapy response and the need for earlier combination therapy. The key is not avoiding certain drug classes, but rather prioritizing effective combinations from the outset 2.